The IAS–USA Annual Virtual Course Update: Emerging Challenges in HIV Medicine

Needs Assessment

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and other emerging challenges in HIV medicine. Information will be presented through a mix of didactic lectures, clinically relevant cases, and discussions developed and led by an expert faculty of clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing ART in clinical circumstances such as regimen simplification, drug resistance, and newly approved or investigational therapies
• Describe emerging investigational ART and potential roles in future HIV treatment
• Apply current evidence on HIV drug resistance, including clinically important resistance mutations, to optimize ART
• Incorporate recent evidence and guideline updates, including findings from the REPRIEVE trial and current AHA recommendations, to reduce cardiovascular disease risk in people with HIV
• Differentiate cognitive decline–related aging from HIV-associated neurologic complications and apply appropriate diagnostic and management strategies

Preliminary Topics

• Cognitive decline in people with HIV: aging and HIV-related neurologic complications
• Investigational ART
• HIV drug resistance updates
• Cardiovascular disease prevention in people with HIV: REPRIEVE and AHA guideline updates
• Challenging ART cases: regimen simplification, drug resistance, and emerging therapies

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 7 or more days before the date of an activity to receive a refund minus a $15 administrative fee. Any requests made within 6 days before the course will not be refunded. Please note: registration substitutions are not permitted.